image credit- shutterstock
Mabwell, a China-based innovation-driven biopharmaceutical company with a fully integrated industry chain, has established a licensing and commercialisation agreement with a strategic business partner in Malaysia for its Denosumab biosimilar products MAILISHU (a biosimilar of Prolia®) and MAIWEIJIAN (a biosimilar of Xgeva®).
Under the agreement, the partner is responsible for the registration and commercialisation of the products in Malaysia, while Mabwell is responsible for the development, production and commercial supply for the products.
Malaysia has a population of approximately 35.97 million, with a GDP at a leading level in Southeast Asia. As a full member of PIC/S, Malaysia boasts the most mature and well-regulated pharmaceutical regulatory framework in the ASEAN region. In terms of the pharmaceutical market, Malaysia's market size stood at approximately $3.4 billion in 2025, maintaining a compound annual growth rate of about 6%, indicating big market potential.
Huiguo Hu, Board Member, Senior Vice President and Board Secretary of Mabwell, said, "Malaysia has an internationally aligned regulatory environment, strong regional recognition and significant space for development. This collaboration will further deepen Mabwell's presence in the ASEAN market. We look forward to rapidly advancing the product's local registration and commercialisation with our partner's strong commercial capabilities, bring high-quality, affordable treatment options to more patients in the region."
